Skye Bioscience, Inc.
SKYE
$1.89
$0.073.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.49M | 11.11M | 13.26M | 9.99M | 7.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.20K | 1.20K | 400.00 | 0.00 | 0.00 |
| Total Operating Expenses | 30.19M | 23.61M | 22.14M | 16.57M | 13.52M |
| Operating Income | -30.19M | -23.61M | -22.14M | -16.57M | -13.52M |
| Income Before Tax | -26.56M | -21.23M | -42.28M | -37.49M | -37.64M |
| Income Tax Expenses | 10.10K | 10.10K | 10.10K | 5.60K | 3.60K |
| Earnings from Continuing Operations | -26.57 | -21.24 | -42.29 | -37.50 | -37.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.57M | -21.24M | -42.29M | -37.50M | -37.64M |
| EBIT | -30.19M | -23.61M | -22.14M | -16.57M | -13.52M |
| EBITDA | -29.90M | -23.46M | -22.02M | -16.45M | -13.40M |
| EPS Basic | -0.73 | -0.84 | -3.91 | -4.50 | -5.69 |
| Normalized Basic EPS | -0.49 | -0.57 | -0.80 | -1.16 | -1.53 |
| EPS Diluted | -0.73 | -0.84 | -3.91 | -4.51 | -5.70 |
| Normalized Diluted EPS | -0.49 | -0.57 | -0.80 | -1.16 | -1.53 |
| Average Basic Shares Outstanding | 145.46M | 117.89M | 86.95M | 52.17M | 27.94M |
| Average Diluted Shares Outstanding | 145.46M | 117.89M | 86.95M | 52.17M | 27.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |